Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Internal urethrotomy versus Optilume™ drug-coated balloon dilatation for the management of anterior urethral strictures: morbidity comparison of the techniques.

World journal of urology·2026
Same author

Cancer detection in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

BJU international·2026
Same author

Outcomes of patients undergoing Optilume<sup>®</sup> drug-coated balloon for different locations of urethral strictures: results from a multicenter cohort.

World journal of urology·2026
Same author

Development and Internal Validation of a Side-Specific Nomogram Integrating mpMRI and Biopsy Features to Guide Nerve-Sparing Decision Making in Prostate Cancer with Capsular Contact.

Cancers·2026
Same author

Prostate Cancer Incidence, Mortality, and Survival in Switzerland.

JAMA network open·2026
Same author

Robocasting as an Additive Manufacturing Method for Oxide Ceramics: A Study of Mechanical Properties and Microstructure.

Materials (Basel, Switzerland)·2025

Related Experiment Video

Updated: Jul 1, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

[Selective application of tumor markers PSA].

Maciej Kwiatkowski1, Petra Stieber, Andreas R Huber

  • 1Urologische Klinik, Kantonsspital Aarau. maciej.kwiatkowski@ksa.ch

Therapeutische Umschau. Revue Therapeutique
|September 16, 2008
PubMed
Summary

Prostate specific antigen (PSA) is crucial for prostate cancer detection and management. Early detection and informed patient choices improve outcomes, while PSA monitoring aids in identifying relapse for timely intervention.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Related Experiment Videos

Last Updated: Jul 1, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Area of Science:

  • Oncology
  • Biomarker Research
  • Urology

Context:

  • Tumor markers are vital for cancer detection, diagnostics, prognosis, therapy, and follow-up.
  • Prostate specific antigen (PSA) is a key tumor marker in oncology, essential for prostate cancer management.
  • Clinical utility of tumor markers is limited by sensitivity and specificity, necessitating selective use for clear patient benefit.

Purpose:

  • To highlight the critical role of Prostate Specific Antigen (PSA) in prostate cancer management.
  • To define optimal diagnostic and follow-up strategies using PSA levels and free-to-total PSA ratios.
  • To emphasize the importance of patient education regarding PSA testing and treatment options.

Summary:

  • PSA is integral to early detection, therapy decisions, and monitoring of prostate cancer.
  • Specific PSA cut-offs and free-to-total PSA ratios guide biopsy decisions, eliminating the "grey zone."
  • Follow-up protocols are stratified by PSA levels and life expectancy, with models aiding in identifying candidates for active surveillance.

Impact:

  • Refined clinical guidelines for PSA utilization in prostate cancer diagnosis and monitoring.
  • Improved patient stratification for active surveillance and timely intervention in cases of relapse.
  • Enhanced understanding of PSA's role in predicting disease progression and guiding salvage therapies.